Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
SwedenIPO:
05 June 2020Website:
http://www.calliditas.seNext earnings report:
13 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Wed, 03 Jul 2024 19:04:41 GMTDividend
Analysts recommendations
Institutional Ownership
CALT Latest News
STOCKHOLM , July 4, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT) (STO: CALTX) ("Calliditas") today announces that its partner Viatris Pharmaceutical Japan G.K. ("Viatris") has initiated a phase III clinical trial in Japan with Nefecon, named VR-205 in the Japanese market, in Japanese patients with IgA nephropathy (IgAN).
STOCKHOLM , June 18, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the United States Patent and Trademark Office (USPTO) has issued a patent for application no. 16/760,910 entitled "Use of NOX Inhibitors for Treatment of Cancer.
STOCKHOLM , June 17, 2024 /PRNewswire/ -- The following resolutions were passed at Calliditas Therapeutics AB (publ) ("Calliditas") annual general meeting held today, on 17 June 2024, in Stockholm. Adoption of income statement and balance sheet for the financial year 2023 and discharge from liability The annual general meeting resolved to adopt the income statement and the consolidated income statement for the financial year 2023 as well as the balance sheet and consolidated balance sheet as of 31 December 2023.
NEW YORK, June 05, 2024 (GLOBE NEWSWIRE) -- Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Calliditas Therapeutics AB ( NASDA Q: CALT ), relating to a tender offer from Asahi Kasei Corporation. Under the terms of the offer, Asahi Kasei Corporation will acquire all the outstanding shares of Calliditas stock for SEK 0.04 in cash per ADS.
NEW YORK , June 4, 2024 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Calliditas Therapeutics AB (NASDAQ: CALT), relating to a tender offer from Asahi Kasei Corporation.
STOCKHOLM , May 30, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas"), today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending the granting of full marketing authorisation for Kinpeygo for the treatment of adults with primary immunoglobulin A nephropathy (IgAN). Kinpeygo, which was granted conditional marketing authorisation in EU on 15 July 2022, was the first ever approved treatment for IgAN in the EU and UK.
STOCKHOLM , May 28, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas"), today announced the presentations of an additional efficacy analysis of Nefecon (TARPEYO® (budesonide) delayed release capsules)) as well as a real-world analysis of the use of systemic glucocorticoids (SGC) in IgA nephropathy (IgAN). These were presented at ERA 2024 virtually and in Stockholm on May 23 - 26, 2024.
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Calliditas Therapeutics AB (NASDAQ: CALT) to Asahi Kasei Corporation for SEK 416 in cash per American Depositary Share is fair to Calliditas shareholders. Halper Sadeh encourages Calliditas shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or [email protected] or [email protected]. The inv.
STOCKHOLM , May 28, 2024 /PRNewswire/ -- The Board of Directors of Calliditas Therapeutics AB (publ) unanimously recommends that the shareholders and holders of American Depositary Shares (" ADS ") of Calliditas Therapeutics AB (publ) (jointly the " Securityholders ") accept the public tender offer by Asahi Kasei Corporation. Background This statement is made by the Board of Directors (the "Board") of Calliditas Therapeutics AB (publ) ("Calliditas" or the "Company") pursuant to section II.19 of the Nasdaq Stockholm takeover rules ("Section II.19") and Regulation 14D under the Securities Exchange Act of 1934, as amended (together with Section II.19, the "Takeover Rules").
Calliditas Therapeutics AB (publ) (NASDAQ:CALT ) Q1 2024 Earnings Conference Call May 23, 2024 8:30 AM ET Company Participants Renee Aguiar-Lucander - CEO Richard Philipson - CMO Maria Tornsen - President, North America Fredrik Johansson - CFO Conference Call Participants Zhiyao Lu - Jefferies Vamil Divan - Guggenheim Securities Ashiq Mubarack - Citi Annabel Samimy - Stifel Christopher Uhde - SEB Enskilda Suzanne van Voorthuizen - VLK Johan Unnerus - Redeye Rami Katkhuda - LifeSci Capital Erik Hultgard - Carnegie Arthur He - HC Wainwright Operator Welcome to the Calliditas Q1 2024 Report. For the first part of the conference call, the participants will be in listen-only mode.
- 1(current)
What type of business is Calliditas Therapeutics AB (publ)?
Calliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It offers Nefecon, an oral formulation of budesonide that is an immunosuppressant for the treatment of the autoimmune renal disease immunoglobulin A nephropathy. The company's lead product candidate is Setanaxib, a NOX inhibitor that is in Phase 2b/3 clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for type 1 diabetic kidney disease. It also develops Budenofalk 3 mg oral capsules for the treatment of autoimmune hepatitis. The company was incorporated in 2004 and is headquartered in Stockholm, Sweden.
What sector is Calliditas Therapeutics AB (publ) in?
Calliditas Therapeutics AB (publ) is in the Healthcare sector
What industry is Calliditas Therapeutics AB (publ) in?
Calliditas Therapeutics AB (publ) is in the Biotechnology industry
What country is Calliditas Therapeutics AB (publ) from?
Calliditas Therapeutics AB (publ) is headquartered in Sweden
When did Calliditas Therapeutics AB (publ) go public?
Calliditas Therapeutics AB (publ) initial public offering (IPO) was on 05 June 2020
What is Calliditas Therapeutics AB (publ) website?
https://www.calliditas.se
Is Calliditas Therapeutics AB (publ) in the S&P 500?
No, Calliditas Therapeutics AB (publ) is not included in the S&P 500 index
Is Calliditas Therapeutics AB (publ) in the NASDAQ 100?
No, Calliditas Therapeutics AB (publ) is not included in the NASDAQ 100 index
Is Calliditas Therapeutics AB (publ) in the Dow Jones?
No, Calliditas Therapeutics AB (publ) is not included in the Dow Jones index
When does Calliditas Therapeutics AB (publ) report earnings?
The next expected earnings date for Calliditas Therapeutics AB (publ) is 13 August 2024